Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis

Flamm, S; Mutimer, D; Asatryan, A; Wang, S; Rockstroh, J; Horsmans, Y; Kwo, PY; Weiland, O; Villa, E; Heo, J; Gane, E; Ryder, SD; Welzel, TM; Ruane, PJ; Agarwal, K; Ng, TI; Xue, ZY; Lovell, SS; Krishnan, P; Kopecky-Bromberg, S; Trinh, R; Mensa, FJ; W

Flamm, S (reprint author), Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.

JOURNAL OF VIRAL HEPATITIS, 2019; 26 (3): 337

Abstract

Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 st......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索